Library / regulatory-reference
Algeria: National Agency for Pharmaceutical Products (ANPP)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The National Agency for Pharmaceutical Products, known by its French initials ANPP, is Algeria's national regulator for medicines and pharmaceutical products, operating under the Ministry of Health.
Algeria is one of North Africa's largest pharmaceutical markets, with a deliberate national policy of building domestic production to reduce import dependence, and the agency's registration and pricing-linked decisions are central to that strategy.
How products enter the market
Medicines require a marketing authorization granted after evaluation of quality, safety and efficacy, with documentation review supported by the national medicines-quality-control laboratory. Import of products already made locally is restricted under the domestic-production policy, which shapes the registration landscape.
The agency licenses establishments, supervises the market, and operates the national pharmacovigilance system in coordination with the health ministry.
Regional and international role
The agency participates in African and Arab regional regulatory cooperation, and Algeria's domestic-production push makes its manufacturing-authorization and inspection decisions consequential for companies seeking entry into the North African market.
Its regulatory development is watched across the Maghreb, where neighboring authorities are undertaking similar institution-building.
Using this profile
The agency publishes registers, guidance and announcements in Arabic and French through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: the ANPP illustrates the industrial-policy-linked regulator: product registration used deliberately alongside domestic-production policy, with market access tied to national manufacturing goals.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.